PE20180742A1 - Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
PE20180742A1
PE20180742A1 PE2017002534A PE2017002534A PE20180742A1 PE 20180742 A1 PE20180742 A1 PE 20180742A1 PE 2017002534 A PE2017002534 A PE 2017002534A PE 2017002534 A PE2017002534 A PE 2017002534A PE 20180742 A1 PE20180742 A1 PE 20180742A1
Authority
PE
Peru
Prior art keywords
branched
straight
linear
alkyl
derivatives
Prior art date
Application number
PE2017002534A
Other languages
English (en)
Spanish (es)
Inventor
Zoltan Szlavik
Andras Kotschy
Maia Chanrion
Didier Demarles
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
Szabolcs Sipos
Attila Paczal
Balazs Balint
Original Assignee
Servier Lab
Vernalis Randd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis Randd Ltd filed Critical Servier Lab
Publication of PE20180742A1 publication Critical patent/PE20180742A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2017002534A 2015-06-23 2016-06-22 Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen PE20180742A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555752A FR3037957B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20180742A1 true PE20180742A1 (es) 2018-04-27

Family

ID=54608634

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002534A PE20180742A1 (es) 2015-06-23 2016-06-22 Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen

Country Status (43)

Country Link
US (2) US10227358B2 (cg-RX-API-DMAC10.html)
EP (1) EP3313851B1 (cg-RX-API-DMAC10.html)
JP (1) JP6741697B2 (cg-RX-API-DMAC10.html)
KR (1) KR102718253B1 (cg-RX-API-DMAC10.html)
CN (1) CN107709333B (cg-RX-API-DMAC10.html)
AR (1) AR105103A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016282836B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017027414B1 (cg-RX-API-DMAC10.html)
CA (1) CA2990088C (cg-RX-API-DMAC10.html)
CL (1) CL2017003258A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017012786A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170564A (cg-RX-API-DMAC10.html)
CU (1) CU20170160A7 (cg-RX-API-DMAC10.html)
CY (1) CY1122542T1 (cg-RX-API-DMAC10.html)
DK (1) DK3313851T3 (cg-RX-API-DMAC10.html)
EA (1) EA033266B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP17081744A (cg-RX-API-DMAC10.html)
ES (1) ES2759480T3 (cg-RX-API-DMAC10.html)
FR (1) FR3037957B1 (cg-RX-API-DMAC10.html)
GE (2) GEAP201914678A (cg-RX-API-DMAC10.html)
HK (1) HK1249506A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20200107T1 (cg-RX-API-DMAC10.html)
HU (1) HUE047889T2 (cg-RX-API-DMAC10.html)
IL (1) IL256270A (cg-RX-API-DMAC10.html)
JO (1) JO3675B1 (cg-RX-API-DMAC10.html)
MA (1) MA42239B1 (cg-RX-API-DMAC10.html)
MD (1) MD3313851T2 (cg-RX-API-DMAC10.html)
MX (1) MX372716B (cg-RX-API-DMAC10.html)
MY (1) MY190561A (cg-RX-API-DMAC10.html)
PE (1) PE20180742A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017502246A1 (cg-RX-API-DMAC10.html)
PL (1) PL3313851T3 (cg-RX-API-DMAC10.html)
PT (1) PT3313851T (cg-RX-API-DMAC10.html)
RS (1) RS59904B1 (cg-RX-API-DMAC10.html)
RU (1) RU2734418C2 (cg-RX-API-DMAC10.html)
SI (1) SI3313851T1 (cg-RX-API-DMAC10.html)
SV (1) SV2017005587A (cg-RX-API-DMAC10.html)
TN (1) TN2017000511A1 (cg-RX-API-DMAC10.html)
TW (1) TWI604844B (cg-RX-API-DMAC10.html)
UA (1) UA122228C2 (cg-RX-API-DMAC10.html)
UY (1) UY36736A (cg-RX-API-DMAC10.html)
WO (1) WO2016207225A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201708460B (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018126898A1 (zh) * 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX385115B (es) * 2017-01-06 2025-03-14 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
IL271475B2 (en) * 2017-06-22 2023-09-01 Servier Lab Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
US12129261B2 (en) * 2018-12-06 2024-10-29 Les Laboratoires Servier Crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2021067827A1 (en) * 2019-10-03 2021-04-08 California Institute Of Technology Mcl1 inhibitors and uses thereof
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
CN113651663B (zh) * 2021-08-20 2024-03-29 浙大宁波理工学院 一种氘代芳香羰基类化合物的制备方法
US20240401146A1 (en) 2021-10-06 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PH12017502246B1 (en) 2018-05-28
US10227358B2 (en) 2019-03-12
MY190561A (en) 2022-04-27
KR20180019223A (ko) 2018-02-23
US10711010B2 (en) 2020-07-14
IL256270A (en) 2018-02-28
HRP20200107T1 (hr) 2020-04-03
EP3313851B1 (en) 2019-11-06
SV2017005587A (es) 2018-04-11
NZ738455A (en) 2024-03-22
UY36736A (es) 2016-12-30
EP3313851A1 (en) 2018-05-02
ZA201708460B (en) 2021-06-30
JP2018522855A (ja) 2018-08-16
CA2990088A1 (en) 2016-12-29
GEP20207074B (en) 2020-03-10
AU2016282836A1 (en) 2018-01-18
TW201709911A (zh) 2017-03-16
JP6741697B2 (ja) 2020-08-19
UA122228C2 (uk) 2020-10-12
DK3313851T3 (da) 2020-01-27
MD3313851T2 (ro) 2020-02-29
JO3675B1 (ar) 2020-08-27
MA42239B1 (fr) 2020-02-28
HK1254657A1 (en) 2019-07-26
BR112017027414B1 (pt) 2023-12-19
ECSP17081744A (es) 2018-02-28
CY1122542T1 (el) 2021-01-27
ES2759480T3 (es) 2020-05-11
CN107709333B (zh) 2021-01-01
US20180170947A1 (en) 2018-06-21
CN107709333A (zh) 2018-02-16
CO2017012786A2 (es) 2018-04-10
PL3313851T3 (pl) 2020-05-18
FR3037957A1 (cg-RX-API-DMAC10.html) 2016-12-30
AR105103A1 (es) 2017-09-06
TN2017000511A1 (en) 2019-04-12
MX372716B (es) 2020-05-28
FR3037957B1 (fr) 2019-01-25
WO2016207225A1 (en) 2016-12-29
KR102718253B1 (ko) 2024-10-16
TWI604844B (zh) 2017-11-11
CA2990088C (en) 2021-04-13
RU2018102365A (ru) 2019-07-23
CR20170564A (es) 2018-02-20
AU2016282836B2 (en) 2020-07-09
US20190161496A1 (en) 2019-05-30
PH12017502246A1 (en) 2018-05-28
GEAP201914678A (en) 2019-11-11
HUE047889T2 (hu) 2020-05-28
RU2734418C2 (ru) 2020-10-16
EA033266B1 (ru) 2019-09-30
MX2017016997A (es) 2018-09-07
SI3313851T1 (sl) 2020-03-31
RS59904B1 (sr) 2020-03-31
EA201890125A1 (ru) 2018-06-29
RU2018102365A3 (cg-RX-API-DMAC10.html) 2019-09-23
CU20170160A7 (es) 2018-05-08
PT3313851T (pt) 2020-01-06
HK1249506A1 (zh) 2018-11-02
CL2017003258A1 (es) 2018-06-01
BR112017027414A2 (pt) 2018-08-28

Similar Documents

Publication Publication Date Title
PE20180949A1 (es) Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20181491A1 (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20200700A1 (es) Compuestos macrociclicos y usos de los mismos
CL2020001546A1 (es) Compuestos de 4-azaindol.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
PE20200937A1 (es) Compuestos macrociclicos para tratar enfermedades
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2017012786A2 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2016002348A1 (es) Agonistas del receptor muscarínico
CL2016002033A1 (es) Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros.
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CL2019000512A1 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2016000904A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
PE20201498A1 (es) Nuevos derivados macrociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20161251A1 (es) Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4
ECSP11011470A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
MX2018005733A (es) Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).
ECSP17069696A (es) Compuestos novedosos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
CO2018003473A2 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
PE20212327A1 (es) Ciertos compuestos de pladienolida y metodos de uso